Reimbursement for optical coherence tomography established in Germany

31

Oct 2019

Reimbursement of optical coherence tomography (OCT) for diagnosis and therapy control in retinal diseases will be available from October 2019 via the EBM (Einheitlicher Bewertungsmaβstab, German Uniform Evaluation Standard).

The OCT imaging technique is based on different reflections of laser light through different tissue layers. The OCT is used in the ophthalmological field, especially for the examination of the retina and allows a representation of the various layers and parts of the retina - similar to histological sectional images. In retinal diseases, OCT should provide early diagnosis of pathological processes before they become noticeable, for example, by a deterioration in vision.

Patients with neovascular age-related macular degeneration or macular edema as a result of diabetic retinopathy are now eligible for the new statutory health insurance service. This was decided by the Federal Joint Committee (G-BA) at the end of 2018.

The National Association of Statutory Health Insurance Physicians (KBV) together with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) have now set the reimbursement for optical coherence tomography (OCT) in the Evaluation Committee and added four new fee order items (GOP) to the EBM for billing.

The health insurance companies will pay €43.18 per eye extrabudgetary.

For the diagnostic of the right eye, ophthalmologists calculate the GOP 06336, on the left eye - the GOP 06337. Both services can be billed once in the treatment case and are rated with 399 points (€43.18).

OCT can also be used to control therapy in the indications listed above. Ophthalmologists, in this case, will calculate the GOP 06338 for the right and the GOP 06339 for the left eye diagnostic. These fee order items are also rated with 399 points (€43.18).

The two GOPs for therapy control can be calculated in addition to the supplementary services provided via GOP 06334 (for the right eye) and 06335 (for left eye) for intravitreal drug administration (IVM), which are already available in EBM. This is possible up to six times in case of disease.

However, the following restriction will apply: the new GOPs 06338 and 06339 cannot be calculated in the period of three weeks after the IVM. Ophthalmologists must state the date of the last IVM on their billing. In addition, the GOP 06338 and 06339 can be calculated only once in the period of 26 days.

The Evaluation Committee has decided to review the new services in two years. If necessary, this will lead to the correction of the current decision.

The full details in German can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

09

Mar 2022

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more